58/100
This weighted demonstration score combines clinical and economic value defensibility with generic anchoring and European price-governance risk.
A premium is achievable but only with sequencing discipline and confidential net prices.
The two pillars limiting the price
Generic anchor at 38 of 100, carrying 22 percent of the weight
Convenience at 48 of 100, carrying 14 percent of the weight
Move a slider to test what happens if a pillar is strengthened or weakened. The overall score is weighted, so effort is worth most where the weight is highest.
The weights, scores and evidence summaries are illustrative and would be configured and validated for the specific asset and markets.
Clinical value over generic standard of care
Weight 26 percent
Finding
A 24 point absolute gain in SRI-4 response and a 41 percent reduction in renal flare give a real, quantified advantage over generics.
Evidence today
One pivotal trial against standard of care plus a 52 week extension. No head to head against the biologic used in refractory patients.
What moves it
Add the renal flare and steroid sparing endpoints to the pivotal publication and pre-agree the comparator with G-BA and HAS before submission.
Convenience and adherence value of the oral formulation
Weight 14 percent
Finding
European payers may treat convenience primarily as a differentiator unless it is linked to measurable improvements in adherence, outcomes, resource use or patient burden.
Evidence today
Patient preference study and an adherence model. No prospective evidence linking adherence to reduced flares or hospital use.
What moves it
Convert convenience into money: model avoided infusion chair time, travel, and monitoring, and generate real world adherence data in year one.
Generic price anchoring and comparator risk
Weight 22 percent
Finding
The low generic cost creates a challenging price anchor. The achievable premium will depend on the accepted comparator, target population and strength of incremental clinical and economic evidence.
Evidence today
Precedent in rare disease where a generic anchor cut the achievable price by more than half.
What moves it
Fight the comparator definition, not the price. Position against the treated refractory pathway including biologics and hospital care, and lead with total cost of the disease.
International reference pricing exposure
Weight 18 percent
Finding
In this simplified demonstration model, several priority markets are assumed to influence prices elsewhere. The exact relationships, timing and use of list or net prices would require country-level validation.
Evidence today
Mapped referencing baskets and observed lag of 9 to 18 months.
What moves it
Sequence launches by referencing influence, hold a single European list corridor, and never publish a low list price to buy volume.
HTA and payer precedent for rare disease premiums
Weight 12 percent
Finding
Illustrative analogue assessments suggest that tolerance for a rare-disease premium varies substantially by market and by the strength of demonstrated added value.
Evidence today
Eleven comparable rare disease launches reviewed across the eight markets.
What moves it
Open with the tolerant markets to build a price record, and cite them as evidence in the German and French negotiations.
Confidential net pricing and ability to hold a corridor
Weight 8 percent
Finding
Confidential arrangements may help maintain a consistent visible price alongside differentiated net prices, subject to country-specific rules and feasibility.
Evidence today
Managed entry and risk sharing mechanisms confirmed in six of eight markets.
What moves it
Make confidentiality a launch precondition. Where a public discount is unavoidable, delay entry rather than accept a visible cut.
The score is a diagnostic framework rather than a conclusion about the price that could be achieved. In this illustration it points to two areas where the case is currently weakest: the generic price anchor, and convenience that is not yet expressed in measurable clinical or economic terms.
Both are areas where pre-launch evidence and comparator framing may have most influence, and both become harder to revisit once a price is on the record in a referenced market. The value of the framework is in showing where evidence and governance effort would move the assessment.